Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Bortezomib, Melphalan, Prednisone (VMP) Followed by Lenalidomide Maintenance vs. VMP Without Maintenance in Myeloma Patients Not Eligible to High-dose Chemotherapy and Autologous Stem Cell Transplantation

NCT02145598 is registered in ClinicalTrials.gov with Dr. med. Lars-Olof Muegge as lead sponsor.

NCT NCT02145598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02145598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Bortezomib, Melphalan, Prednisone (VMP) Followed by Lenalidomide Maintenance vs. VMP Without Maintenance in Myeloma Patients Not Eligible to High-dose Chemotherapy and Autologous Stem Cell Transplantation
Lead sponsor
Dr. med. Lars-Olof Muegge
Phase
Phase 2/3
Overall status
Terminated
Start date
August 31, 2013
Completion date
December 31, 2018
Enrollment
85 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma